David Cachia is a Neurology physician affiliated with UMass Memorial Health Care. OpenAlex indexes 125 publications with 1,601 citations (h-index 20).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Lake Ave N
Worcester, MA 016550002
Telephone
508-334-3550Provider last certified this registry record 13 May 2026.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novocure Inc.Program year20251 payment
- Telix PharmaceuticalsProgram year20241 payment
- GT Medical Technologies, IncProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
71.6%Other antiepileptics51.4%Levetiracetam73%Lacosamide27%Part D<11 patientsAnti-epileptic Agent10.1%Zonisamide100%Part D<11 patients+ 1 more class in this area
Sensory organs
14.7%Corticosteroid14.7%Dexamethasone100%Part D≥12 patientsMetabolism & gastrointestinal
13.8%Serotonin-3 Receptor Antagonist13.8%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors
Journal of Neuro-Oncology
2024 - Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma
Journal of Neuro-Oncology
2024 - Diffusely invasive supratentorial rosette-forming glioneuronal tumor: illustrative case
Journal of Neurosurgery Case Lessons
2023 - Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic <i>NF2</i> Mutations
Journal of Clinical Oncology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Gerard Aurigemma, MD
UMass Memorial Health Care
Richard Irwin, MD
UMass Memorial Health Care
Craig Lilly, MD
UMass Memorial Health Care
David Keefe, MD
UMass Memorial Health Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”